DSS Takara Bio India Private Limited (DTI), the joint venture between DSS Imagetech Private Limited., India, and Takara Bio Inc., Japan, is celebrating 15 years of advancing life-science research, biotechnology and molecular diagnostics in India. 

Built on a shared India-Japan vision, DTI has grown from a technology access partnership into a national platform for world-class molecular biology manufacturing, scientific support and research-led innovation.

At the heart of this milestone is a powerful Make in India story. DTI today manufactures over 100 molecular biology reagents and enzymes at its ISO-certified facility in New Delhi, making it one of India's leading manufacturers of molecular biology reagents and enzymes. 

The facility has end-to-end manufacturing capabilities for molecular biology reagents and critical enzymes, with an annual production capacity exceeding 20 million units, supported by an increasing focus on local sourcing, robust quality systems and supply resilience.

For Indian scientists, this has translated into faster, more reliable and more affordable access to advanced tools for PCR, qPCR, next-generation sequencing, gene expression, cell biology, stem cell research, protein analysis and translational research. 

By localising key products and building strong application support across the country, DTI has helped reduce dependence on imports while enabling researchers, diagnostic laboratories and biopharmaceutical companies to work with globally benchmarked technologies made available in India.

“This 15-year milestone is not only a celebration of a successful India-Japan partnership; it is also a celebration of India’s growing confidence in high-quality biotechnology manufacturing,” said Harkaran Dhingra, CEO, DSS Takara Bio India. 

“DSS Takara Bio India brings together Japanese innovation, Indian scientific talent and a deep commitment to enabling research in India. Our ambition is to build DTI as a Make in India for the World organization — one that supports discovery, diagnostics, precision medicine and the next phase of biotechnology growth from India,” Dhingra added further.